Quick Answer
Vaxcyte, Inc. reported R&D Expense of $794.31 million for fiscal year 2025.
Vaxcyte, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $794.31M | +66.6% |
| 2024 | $476.64M | +43.4% |
| 2023 | $332.34M | +96.1% |
| 2022 | $169.45M | +116.1% |
| 2021 | $78.41M | +6.6% |
| 2020 | $73.56M | +61.3% |
| 2019 | $45.61M | +51.3% |
| 2018 | $30.14M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $209.93M | +79.5% | +8.1% |
| June 30, 2025 | $194.18M | +47.7% | +31.1% |
| March 31, 2025 | $148.13M | +56.6% | +26.7% |
| September 30, 2024 | $116.94M | +20.0% | -11.1% |
| June 30, 2024 | $131.51M | +80.9% | +39.0% |
| March 31, 2024 | $94.59M | +62.9% | -2.9% |
| September 30, 2023 | $97.42M | +104.3% | +34.0% |
| June 30, 2023 | $72.69M | +89.0% | +25.2% |
- Vaxcyte, Inc. showed an increase of +66.6% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Vaxcyte, Inc.’s r&d expense has grown by 2535.0% (from $30.14 million to $794.31 million).
- The most recent figure is from Vaxcyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: